PDF
Full
Outline
To systematically analyze the pharmacokinetic parameters, oral bioavailability and in vivo metabolites of trilobatin in Sprague-Dawley (SD) rats using liquid chromatography - triple quadrupole mass spectrometry (LC-MS/MS).
The chromatographic conditions were performed on an ACQUITY UPLC BEH C18 column (50 mm×2.1 mm, 1.7 µm) with 0.1% formic acid (mobile phase A) and acetonitrile (mobile phase B) as the mobile phase. A gradient elution program was carried out with an accompanying flow rate of 0.3 mL·min-1, a column temperature of 40 ℃, and an injection volume of 2 μL. The mass spectrometry conditions comprised an electrospray ion source in conjunction with negative ionization mode, with an ionogenic temperature of 150 ℃, a capillary voltage of -3.0 kV, and a desolvation-gas flow temperature of 500 ℃. The desolvation-gas flow rate was set at 750 L·h-1, and the conical pore gas volumetric flow rate was fixed at 150 L·h-1. The analysis was conducted in multiple reaction monitoring mode. Trilobatin was given to rats via gavage and intravenous injection, respectively. Plasma, urine and fecal samples were collected, and the drug concentration was determined after methanol precipitation of proteins. Pharmacokinetic parameters and metabolites were analyzed by pharmacokinetic software and metabolite analysis and identification software.
Following the administration of trilobatin to SD rats at a dose of 100 mg·kg-1 via gavage and intravenous injection, respectively. The area under the curve (AUC0-t) was found to be (423.98 ± 295.42) ng·h·mL-1 and (90 894.75 ± 25 472.44) ng·h·mL-1, respectively. The oral bioavailability was determined to be 0.46%; Cmax was (203.83±25.88) ng·mL-1 and (181 814.90±113 461.60) ng·mL-1, respectively. The oral half-life was 1.65 h, while the intravenous half-life was 3.82 h. Trilobatin was metabolized to phloretin in the intestine and underwent further biotransformation in vivo through deglycosylation, methylation, deoxygenation and hydrolysis.
The pilot study represents a preliminary investigation into the in vivo pharmacokinetics and metabolism of trilobatin in rats, providing a foundation for further pharmacodynamics research and subsequent formulation development.
PDF
93
40
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
